Kura Oncology Inc Stock Price, News & Analysis

Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer treatments, will participate in Stifel's 2023 Targeted Oncology Days. CEO Troy Wilson is set to appear in a virtual fireside chat on April 25, 2023, at 1:00 p.m. ET. Investors can access a live audio webcast on Kura's website, with an archived replay available post-event.

Kura's pipeline includes ziftomenib, targeting NPM1-mutant relapsed or refractory acute myeloid leukemia (AML), currently in a Phase 2 trial. Additionally, tipifarnib is in a Phase 1/2 trial for PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC). Kura also plans to initiate trials for KO-2806, a next-gen therapy for advanced solid tumors.

Kura Oncology, Inc. (Nasdaq: KURA) announced promising preclinical data showing the potential of farnesyl transferase inhibitors (FTIs) to treat solid tumors. These findings were presented at the AACR Annual Meeting, highlighting the synergistic effects of tipifarnib combined with targeted therapies like KRAS^G12C inhibitors and TKIs. Kura plans to initiate the Phase 1 dose-escalation trial (FIT-001) of KO-2806, a next-generation FTI, later this year, focusing on its safety and effectiveness as a monotherapy and in combination therapies. The company aims for KO-2806 to address adaptive resistance mechanisms that limit the effectiveness of current targeted cancer therapies.

Kura Oncology (Nasdaq: KURA) announced the acceptance of two abstracts for presentation at the AACR Annual Meeting in Orlando, scheduled from April 14-19, 2023. The presentations will showcase preclinical data on combining farnesyl transferase inhibitors (FTIs) with KRAS^G12C inhibitors and tyrosine kinase inhibitors, which may help prevent resistance to targeted therapies. The company recently received FDA clearance for the Investigational New Drug application of KO-2806, a next-generation FTI, and plans to initiate the FIT-001 Phase 1 trial later this year.

SAN DIEGO, March 1, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer medicines, announced that CEO Troy Wilson will participate in several investor conferences. Key events include:

• A “Leukemia Corporate Panel” at the Cowen Health Care Conference in Boston on March 8, 2023, at 12:50 p.m. ET.
• A fireside chat at the Cowen Health Care Conference on the same day at 2:50 p.m. ET.
• A fireside chat at the Barclays Global Healthcare Conference in Miami on March 14, 2023, at 2:35 p.m. ET.

Live webcasts will be available on Kura's website, with archived replays post-event.

Kura Oncology reported promising Phase 1 data for ziftomenib, showing a 30% complete response (CR) rate among 20 patients with NPM1-mutant AML. Ziftomenib is now in a registration-directed trial (KOMET-001) aiming for up to 85 patients. The company has cleared the IND for KO-2806, its next-generation farnesyl transferase inhibitor. Kura received a $25 million investment from Bristol Myers Squibb, boosting its cash reserves to $438 million, sufficient to fund operations into Q4 2025. The company plans multiple combination trials for ziftomenib, marking potential growth in precision cancer medicine.

Kura Oncology, Inc. (Nasdaq: KURA) will release its fourth quarter and full year 2022 financial results on February 23, 2023, after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide corporate updates. Kura is focused on precision medicine for cancer, with ongoing trials for its drug candidates. Ziftomenib is in a registration-directed trial for NPM1-mutant acute myeloid leukemia, while Tipifarnib has received Breakthrough Therapy Designation in treating HRAS-mutant head and neck squamous cell carcinoma. To join the call, U.S. callers can dial 1-877-407-4018.

Kura Oncology (Nasdaq: KURA) announced the initiation of its KOMET-001 Phase 2 trial for ziftomenib, a novel menin inhibitor targeting NPM1-mutant relapsed or refractory acute myeloid leukemia (AML). This follows promising Phase 1 results, which showed a 30% complete response rate among 20 patients at the recommended dosage of 600 mg. The Phase 2 trial aims to enroll 85 patients across the U.S. and Europe, focusing on complete response and safety as primary endpoints. Ziftomenib has received Orphan Drug Designation from the FDA, underscoring its potential in addressing the high unmet needs of AML patients with NPM1 mutations.

Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer therapies, announced its participation in the virtual SVB Securities Global Biopharma Conference. CEO Troy Wilson will engage in a fireside chat at 5:00 p.m. ET on February 14, 2023. A live audio webcast will be accessible on Kura's website, with an archived replay available thereafter. Kura's pipeline includes Ziftomenib for acute myeloid leukemia and Tipifarnib, which has received Breakthrough Therapy Designation for HRAS-mutant head and neck squamous cell carcinoma. Kura is also advancing KO-2806 through early clinical studies.